Non‐lipid properties of statins
Explore this paper's citation graph
Summary
Regulate plaque stability and thrombosis Coronary artery disease (CAD) remains one of the Inhibition of platelet aggregation main causes of death in adults and decreasing the Reduction inThrombogenic response mortality and morbidity from this condition continues.
- Type
- dissertation
- Published
- 1999-02-01
- Cited by
- 8
- References
- 23
- Access
- Open access
- OpenAlex
- https://openalex.org/W10319901
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:30262286
Keywords
Humanities, Art, Political science
References
- Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
- Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials.
- The Framingham study.
- The emerging role of statins in the prevention of coronary heart disease
- Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys.
- Comparative effect of pravastatin and simvastatin on platelet-thrombus formation in hypercholesterolemic coronary patients
- Is vascular smooth muscle cell proliferation beneficial?
- Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels.
- Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.
- Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: in vitro and in vivo studies.
- High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study.
- Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia.
- Statins do more than just lower cholesterol.
- Platelet function in hyperlipoproteinemia.
- The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.
- Reversing risk in coronary disease.
- Endothelial cell activation
Cited by
- Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro.
- Angina and its treatment
- Circulating Monocytes and Plasma Inflammatory Biomarkers in Active Crohn's Disease: Elevated Oxidized Low-density Lipoprotein and the Anti-inflammatory Effect of Atorvastatin
- Pravastatin down-regulates inflammatory mediators in human monocytes in vitro.
- Chromatography-mass spectrometry methods for the quantitation of statins in biological samples.
- Anti-oxidant therapy for the treatment of coronary artery disease.
- Development of MEPS-UHPLC-MS/MS multistatin methods for clinical analysis.
Related papers
No related papers recorded.